Zambia Signs US$213 Million Joint Venture for Vaccine Manufacturing Plant

On 2 November, Zambia’s Industrial Development Corporation and China’s Jijia International Medical Technology signed a joint venture agreement for ZAMVAX, a vaccine manufacturing project valued at approximately US$213 million across two phases. Phase one is estimated at US$24.13 million and will establish a cholera vaccine fill-and-finish facility in Lusaka, with planned capacity of up to 20 million doses annually. The project offers opportunities for pharmaceutical equipment suppliers, packaging companies, cold-chain providers and technical specialists. HPC can support supplier sourcing and international business partnerships.

If you are interested to enquire further, please fill in the form below with your details and one of our consultants will contact you shortly.